Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 79

1.

Considering the role of incidental appendectomy during colonic interposition gastroesophageal reconstruction.

Dugan M, Sosin M, Caso R, Vadlamudi C, Bayasi M, Marshall MB.

J Thorac Cardiovasc Surg. 2018 Oct 28. pii: S0022-5223(18)32864-2. doi: 10.1016/j.jtcvs.2018.10.090. [Epub ahead of print] No abstract available.

PMID:
30501948
2.

Education, enjoyment, and empowerment: Outcomes of an adolescent transplant camp (I own it).

Kesavarapu K, Palle SK, Dugan M, Antinerella S, Luetkemeyer S, Gupta N.

Pediatr Transplant. 2018 Jun 19:e13236. doi: 10.1111/petr.13236. [Epub ahead of print]

PMID:
29920882
3.

Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma.

Wehrenberg-Klee E, Goyal L, Dugan M, Zhu AX, Ganguli S.

Cardiovasc Intervent Radiol. 2018 Nov;41(11):1799-1802. doi: 10.1007/s00270-018-1993-1. Epub 2018 May 29.

PMID:
29845347
4.

Improving Physical Assessment Observational Skills in the Community Setting: An Experiential Exercise.

Dugan M.

Creat Nurs. 2018 Apr 1;24(1):24-28. doi: 10.1891/1078-4535.22.1.24.

PMID:
29669651
5.

Cryptococcal Meningoencephalitis Complicated by Subdural Empyema in an 8-Year-Old Girl With Neonatal-Onset Multisystem Inflammatory Disease Syndrome: A Rare Sequela.

Pangonis S, Dugan M, Beth Hogan M, Patrizi S.

J Pediatric Infect Dis Soc. 2018 May 15;7(2):e47-e51. doi: 10.1093/jpids/pix069. No abstract available.

PMID:
28992083
6.

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, Hochmair M, Cortot AB, Tsai CM, Moro-Sibilot D, Campelo RG, McCulloch T, Sen P, Dugan M, Pantano S, Branle F, Massacesi C, de Castro G Jr.

Lancet. 2017 Mar 4;389(10072):917-929. doi: 10.1016/S0140-6736(17)30123-X. Epub 2017 Jan 24. Erratum in: Lancet. 2017 Mar 4;389(10072):908.

PMID:
28126333
7.

Fabricating Nanometer-Thick Simultaneously Oleophobic/Hydrophilic Polymer Coatings via a Photochemical Approach.

Wang Y, Dugan M, Urbaniak B, Li L.

Langmuir. 2016 Jul 5;32(26):6723-9. doi: 10.1021/acs.langmuir.6b00802. Epub 2016 Jun 20.

PMID:
27249169
8.

Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

Caldemeyer L, Dugan M, Edwards J, Akard L.

Curr Hematol Malig Rep. 2016 Apr;11(2):71-9. doi: 10.1007/s11899-016-0309-2. Review.

PMID:
26922746
9.

Monolithic optofluidic ring resonator lasers created by femtosecond laser nanofabrication.

Chandrahalim H, Chen Q, Said AA, Dugan M, Fan X.

Lab Chip. 2015 May 21;15(10):2335-40. doi: 10.1039/c5lc00254k.

10.

Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer.

Ades S, Kumar S, Alam M, Goodwin A, Weckstein D, Dugan M, Ashikaga T, Evans M, Verschraegen C, Holmes CE.

J Thromb Haemost. 2015 Jun;13(6):998-1003. doi: 10.1111/jth.12910. Epub 2015 Apr 23.

11.

Interpretation of urine drug testing results in patients using transdermal buprenorphine preparations for the treatment of chronic noncancer pain.

Markman JD, Barbosa WA, Gewandter JS, Frazer M, Rast S, Dugan M, Nandigam K, Villareal A, Kwong TC.

Pain Med. 2015 Jun;16(6):1132-6. doi: 10.1111/pme.12740. Epub 2015 Mar 20.

PMID:
25800409
12.

The Great Diseases Project: a partnership between Tufts Medical School and the Boston public schools.

Jacque B, Malanson K, Bateman K, Akeson B, Cail A, Doss C, Dugan M, Finegold B, Gauthier A, Galego M, Roundtree E, Spezzano L, Meiri KF.

Acad Med. 2013 May;88(5):620-5. doi: 10.1097/ACM.0b013e31828b50fb.

13.

Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib.

Wang X, Kay A, Anak O, Angevin E, Escudier B, Zhou W, Feng Y, Dugan M, Schran H.

J Clin Pharmacol. 2013 Jan;53(1):14-20. doi: 10.1177/0091270011433330. Epub 2013 Jan 24.

PMID:
23400739
14.

Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program.

Shaughnessy P, Uberti J, Devine S, Maziarz RT, Vose J, Micallef I, Jacobsen E, McCarty J, Stiff P, Artz A, Ball ED, Berryman R, Dugan M, Joyce R, Hsu FJ, Johns D, McSweeney P.

Bone Marrow Transplant. 2013 Jun;48(6):777-81. doi: 10.1038/bmt.2012.219. Epub 2012 Nov 26.

PMID:
23178544
15.

Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788.

Baselga J, Mita AC, Schöffski P, Dumez H, Rojo F, Tabernero J, DiLea C, Mietlowski W, Low C, Huang J, Dugan M, Parker K, Walk E, van Oosterom A, Martinelli E, Takimoto CH.

Clin Cancer Res. 2012 Nov 15;18(22):6364-72. doi: 10.1158/1078-0432.CCR-12-1499. Epub 2012 Sep 26.

16.

Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients.

Reardon DA, Conrad CA, Cloughesy T, Prados MD, Friedman HS, Aldape KD, Mischel P, Xia J, DiLea C, Huang J, Mietlowski W, Dugan M, Chen W, Yung WK.

Cancer Chemother Pharmacol. 2012 Jun;69(6):1507-18. doi: 10.1007/s00280-012-1854-6. Epub 2012 Mar 7.

17.

Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma.

Reardon DA, Cloughesy T, Rich J, Alfred Yung WK, Yung L, DiLea C, Huang J, Dugan M, Mietlowski W, Maes A, Conrad C.

Cancer Chemother Pharmacol. 2012 Jan;69(1):281-7. doi: 10.1007/s00280-011-1754-1. Epub 2011 Oct 9.

PMID:
21984222
18.

Costoclavicular venous decompression in patients with threatened arteriovenous hemodialysis access.

Glass C, Dugan M, Gillespie D, Doyle A, Illig K.

Ann Vasc Surg. 2011 Jul;25(5):640-5. doi: 10.1016/j.avsg.2010.12.020. Epub 2011 Apr 21.

PMID:
21514107
19.

Quasi-phase matched second-harmonic generation through thermal poling in femtosecond laser-written glass waveguides.

Li G, Winick KA, Said AA, Dugan M, Bado P.

Opt Express. 2009 May 25;17(11):9442-53.

PMID:
19466197
20.

Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.

Grunberg SM, Dugan M, Muss H, Wood M, Burdette-Radoux S, Weisberg T, Siebel M.

Support Care Cancer. 2009 May;17(5):589-94. doi: 10.1007/s00520-008-0535-9. Epub 2008 Nov 27.

PMID:
19037667

Supplemental Content

Loading ...
Support Center